EyePoint, Inc. (EYPT) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 10, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EYPT SEC filings page.
EyePoint, Inc. (EYPT) reported $2.8M in revenue over the twelve months to Jun 30, 2026, down 94.6% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
EyePoint is funding a development-heavy business: revenue shrank while research spending surged, making losses increasingly cash-based.
Cash conversion deteriorated sharply: FY2025 operating cash flow was-$240.1M against a net loss of$232.0M , whereas FY2023 produced$1.9M of operating cash flow despite a-$70.8M net loss. The shift indicates that recent losses are being accompanied by substantial cash spending rather than mainly reflecting non-cash accounting charges or working-capital timing.
Research and development became the dominant economic commitment, reaching
External funding is carrying the investment cycle: FY2025 financing provided
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of EyePoint, Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
EyePoint, Inc. held $306.1M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $240.1M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and EyePoint, Inc. scores 39/100 among other emerging companies.
EyePoint, Inc. had 83M shares outstanding at the end of fiscal year 2025, against 69M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and EyePoint, Inc. scores 27/100 among other emerging companies.
EyePoint, Inc. spent $221.0M on research and development in fiscal year 2025, which was 80.4% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and EyePoint, Inc. scores 98/100 among other emerging companies.
EyePoint, Inc. reported revenue of $31.4M in fiscal year 2025, against $43.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and EyePoint, Inc. scores 22/100 among other emerging companies.
Not available for EyePoint, Inc., and counted as zero in the overall score.
EyePoint, Inc.'s cash, cash equivalents and investments came to $306.1M at the end of fiscal year 2025, against $57.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and EyePoint, Inc. scores 90/100 among other emerging companies.
EyePoint, Inc. scores -2.37, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($293.1M) relative to total liabilities ($57.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
EyePoint, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
EyePoint, Inc. reported a net loss of $232.0M while operations used $240.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
EyePoint, Inc. reported an operating loss of $243.4M against $33K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
EyePoint, Inc. generated $507K in revenue in Q2 2026. This represents a decrease of 90.5% from the same quarter a year earlier. Against the prior quarter it is down 27.2%.
EyePoint, Inc.'s EBITDA was -$96.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 56.7% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.
EyePoint, Inc. reported -$94.5M in net income in Q2 2026. This represents a decrease of 59.0% from the same quarter a year earlier. Against the prior quarter it is down 11.4%.
EyePoint, Inc. earned -$1.09 per diluted share (EPS) in Q2 2026. This represents a decrease of 28.2% from the same quarter a year earlier. Against the prior quarter it is down 10.1%.
Cash & Balance Sheet
EyePoint, Inc. recorded an outflow of $63.5M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 0.4% from the same quarter a year earlier. Against the prior quarter it is up 22.1%.
EyePoint, Inc. held $110.5M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
EyePoint, Inc.'s ROE was -56.8% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 32.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 20.0 percentage points.
Not reported for Q2 2026.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
EyePoint, Inc. invested $83.6M in research and development in Q2 2026. This represents an increase of 50.7% from the same quarter a year earlier. Against the prior quarter it is up 15.9%.
EyePoint, Inc. invested $1.2M in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 1.6% from the same quarter a year earlier. Against the prior quarter it is up 20.4%.
Not reported for Q2 2026.
EYPT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $507K-90.5% | $696K-97.2% | $619K-94.7% | $966K-90.8% | $5.3M-43.7% | $24.5M+109.3% | $11.6M-17.4% | $10.5M-30.8% |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $736K-38.8% |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $9.8M-30.1% |
| R&D Expenses | $83.6M+50.7% | $72.1M+23.2% | $59.2M+36.4% | $47.8M+61.6% | $55.5M+86.1% | $58.6M+94.3% | $43.4M+141.9% | $29.5M+70.1% |
| SG&A Expenses | $14.2M+20.1% | $15.2M+9.9% | $11.4M-9.2% | $14.5M+11.7% | $11.9M-7.0% | $13.9M-1.6% | $12.5M+11.5% | $13.0M+22.9% |
| Operating Income | -$97.4M-56.5% | -$87.2M-78.6% | -$70.3M-55.5% | -$62.0M-89.4% | -$62.2M-80.1% | -$48.8M-46.6% | -$45.2M-176.6% | -$32.7M-127.4% |
| EBITDA | -$96.7M-56.7% | -$86.6M-79.1% | -$69.6M-55.6% | -$61.4M-90.0% | -$61.7M-80.5% | -$48.3M-46.4% | -$44.8M | -$32.3M |
| Income Tax | $0-100.0% | -$50K | $186K | $0 | $93K | $0 | N/A | $0 |
| Net Income | -$94.5M-59.0% | -$84.8M-87.7% | -$67.6M-63.3% | -$59.7M-103.4% | -$59.4M-92.8% | -$45.2M-54.3% | -$41.4M-193.6% | -$29.4M-132.8% |
| EPS (Basic) | -$1.09-28.2% | -$0.99-52.3% | -$0.82-26.2% | -$0.85-57.4% | -$0.85-46.6% | -$0.65-18.2% | -$0.65-103.1% | -$0.54-63.6% |
| EPS (Diluted) | -$1.09-28.2% | -$0.99-52.3% | -$0.82-26.2% | -$0.85-57.4% | -$0.85-46.6% | -$0.65-18.2% | -$0.65-103.1% | -$0.54 |
| Diluted Shares (Avg) | 86,543+23.8% | 85,999+23.3% | N/A | 70,168+28.9% | 69,926+31.4% | 69,767-99.9% | N/A | 54,449 |
Not reported in any period shown, so not listed: Interest Expense.
EYPT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $228.2M-24.2% | $288.2M-20.5% | $364.0M-13.0% | $251.7M-16.4% | $301.1M-7.1% | $362.6M+10.1% | $418.5M+17.8% | $300.9M+88.0% |
| Current Assets | $188.8M-28.8% | $249.5M-23.7% | $328.7M-14.3% | $216.1M-19.5% | $265.3M-10.1% | $327.0M+2.9% | $383.3M+11.2% | $268.5M+78.8% |
| Cash & Equivalents | $110.5M+55.3% | $77.7M-8.7% | $101.8M+2.1% | $74.6M-6.6% | $71.1M-21.6% | $85.2M-68.6% | $99.7M-64.6% | $79.8M-40.0% |
| Short-Term Investments | $70.0M-62.1% | $144.8M-37.8% | $204.3M-24.7% | $129.4M-25.6% | $184.6M-2.6% | $233.0M+722.4% | $271.2M+444.7% | $174.0M+5743.6% |
| Inventory | $1.9M-29.7% | $1.3M-41.3% | $1.8M-21.3% | $2.1M-24.8% | $2.7M-27.1% | $2.1M-50.0% | $2.3M-41.0% | $2.8M-38.7% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $61.8M+12.0% | $57.7M-10.0% | $57.9M-29.4% | $51.5M-37.3% | $55.1M-42.5% | $64.2M-19.1% | $82.0M-7.8% | $82.2M-19.0% |
| Current Liabilities | $41.9M+26.4% | $37.5M-10.1% | $37.0M-24.5% | $30.1M-38.3% | $33.2M-46.6% | $41.7M-33.4% | $49.0M-22.5% | $48.8M-23.6% |
| Non-Current Liabilities | $19.8M-9.7% | $20.3M-9.8% | $20.9M-36.6% | $21.4M-35.9% | $22.0M-35.1% | $22.5M+34.4% | $32.9M+28.6% | $33.4M-11.0% |
| Total Equity | $166.4M-32.4% | $230.5M-22.8% | $306.1M-9.0% | $200.2M-8.5% | $246.0M+7.8% | $298.4M+19.4% | $336.5M+26.4% | $218.7M+273.1% |
| Retained Earnings | -$1.3B-31.4% | -$1.2B-29.6% | -$1.1B-26.6% | -$1.0B-24.7% | -$977.6M-21.9% | -$918.2M-19.0% | -$873.0M-17.6% | -$831.6M-14.2% |
Not reported in any period shown, so not listed: Accounts Receivable, Goodwill, Long-Term Debt.
EYPT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$62.3M+0.4% | -$80.5M-51.6% | -$65.0M-81.4% | -$59.4M-52.1% | -$62.6M-210.2% | -$53.1M-70.4% | -$35.8M-55.1% | -$39.0M-156.7% |
| Depreciation & Amortization | $690K+28.3% | $636K+28.0% | $698K+49.5% | $576K+41.2% | $538K+48.6% | $497K+64.0% | $467K+317.0% | $408K |
| Stock-Based Compensation | $10.4M+51.2% | $11.6M+48.8% | N/A | N/A | $6.9M-20.9% | $7.8M-38.4% | N/A | $7.4M+105.2% |
| Capital Expenditures | $1.2M-1.6% | $997K+261.2% | $986K+156.8% | $798K-49.3% | $1.2M+35.6% | $276K-76.9% | $384K-56.5% | $1.6M-8.5% |
| Free Cash Flow | -$63.5M+0.4% | -$81.5M-52.7% | -$66.0M-82.2% | -$60.2M-48.2% | -$63.8M-202.7% | -$53.4M-65.0% | -$36.2M-51.0% | -$40.6M-139.9% |
| Investing Cash Flow | $75.1M+55.4% | $59.1M+49.4% | -$74.7M+22.2% | $55.4M+242.0% | $48.3M+130.1% | $39.5M+90.0% | -$96.0M-103.5% | $16.2M+1041.6% |
| Financing Cash Flow | $20.0M+8300.0% | -$2.6M-174.9% | $167.0M+10.1% | $7.4M-37.8% | $238K-27.7% | -$951K-927.0% | $151.7M-30.6% | $11.9M+14.8% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
EYPT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 93.0%+0.9pp |
| Operating Margin | -19207.1% | -12532.5% | -11364.3% | -6420.8% | -1166.8% | -199.7% | -390.4% | -311.2% |
| Net Margin | -18633.1% | -12188.5% | -10922.3% | -6183.4% | -1114.3% | -184.8% | -357.3% | -279.0% |
| Return on Equity | -56.8%-32.6pp | -36.8%-21.7pp | -22.1%-9.8pp | -29.8%-16.4pp | -24.2%-10.7pp | -15.2%-3.4pp | -12.3%-7.0pp | -13.4%+8.1pp |
| Return on Assets | -41.4%-21.7pp | -29.4%-17.0pp | -18.6%-8.7pp | -23.7%-14.0pp | -19.7%-10.2pp | -12.5%-3.6pp | -9.9%-5.9pp | -9.8%-1.9pp |
| Current Ratio | 4.50-3.5x | 6.66-1.2x | 8.88+1.1x | 7.18+1.7x | 8.00+3.2x | 7.85+2.8x | 7.81+2.4x | 5.50+3.2x |
| Debt-to-Equity | 0.37+0.1x | 0.250.0x | 0.19-0.1x | 0.26-0.1x | 0.22-0.2x | 0.21-0.1x | 0.24-0.1x | 0.38+0.4x |
| Asset Turnover | 0.000.0x | 0.00-0.1x | 0.000.0x | 0.000.0x | 0.020.0x | 0.070.0x | 0.030.0x | 0.04-0.1x |
| FCF Margin | -12534.1% | -11716.4% | -10667.7% | -6226.9% | -1196.5% | -218.4% | -312.7% | -385.8% |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| EyePoint, Inc. EYPT | FY2025 | $31.4M | -$232.0M | N/A | $293.1M | 46/100 |
| uniQure N.V. QURE | FY2025 | $16.1M | -$199.0M | N/A | $1.6B | 44/100 |
| UroGen Pharma Ltd. URGN | FY2025 | $109.8M | -$153.5M | N/A | $1.8B | 42/100 |
| Praxis Precision Medicines, Inc. PRAX | FY2025 | $0 | -$303.0M | N/A | $7.3B | — |
| Upstream Bio, Inc. UPB | FY2025 | $2.9M | -$143.4M | N/A | $257.4M | 54/100 |
Where EyePoint, Inc. Ranks
Frequently Asked Questions
What is EyePoint, Inc.'s annual revenue?
EyePoint, Inc. (EYPT) reported $31.4M in total revenue for fiscal year 2025. This represents a -27.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is EyePoint, Inc.'s revenue growing?
EyePoint, Inc. (EYPT) revenue declined by 27.5% year-over-year, from $43.3M to $31.4M in fiscal year 2025.
Is EyePoint, Inc. profitable?
No, EyePoint, Inc. (EYPT) reported a net income of -$232.0M in fiscal year 2025.
What is EyePoint, Inc.'s EBITDA?
EyePoint, Inc. (EYPT) had EBITDA of -$241.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is EyePoint, Inc.'s return on equity (ROE)?
EyePoint, Inc. (EYPT) has a return on equity of -75.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is EyePoint, Inc.'s free cash flow?
EyePoint, Inc. (EYPT) recorded an outflow of $243.4M in free cash flow during fiscal year 2025. This represents a -86.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is EyePoint, Inc.'s operating cash flow?
EyePoint, Inc. (EYPT) recorded an outflow of $240.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are EyePoint, Inc.'s total assets?
EyePoint, Inc. (EYPT) had $364.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are EyePoint, Inc.'s capital expenditures?
EyePoint, Inc. (EYPT) invested $3.3M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does EyePoint, Inc. spend on research and development?
EyePoint, Inc. (EYPT) invested $221.0M in research and development during fiscal year 2025.
What is EyePoint, Inc.'s current ratio?
EyePoint, Inc. (EYPT) had a current ratio of 8.88 as of fiscal year 2025, which is generally considered healthy.
What is EyePoint, Inc.'s debt-to-equity ratio?
EyePoint, Inc. (EYPT) had a debt-to-equity ratio of 0.19 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is EyePoint, Inc.'s return on assets (ROA)?
EyePoint, Inc. (EYPT) had a return on assets of -63.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is EyePoint, Inc.'s P/E ratio?
EyePoint, Inc. (EYPT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $293.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is EyePoint, Inc.'s price-to-sales ratio?
EyePoint, Inc. (EYPT) trades at 105x sales, its market capitalization divided by revenue of $2.8M revenue, trailing 12 months to June 30, 2026. The market capitalization is $293.1M as of Oct 10, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does EyePoint, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, EyePoint, Inc. (EYPT) held $306.1M in cash, cash equivalents and investments, and reported an operating cash outflow of $240.1M over that year. Dividing the one by the other, the reported balance equals about 15 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is EyePoint, Inc.'s Altman Z-Score?
EyePoint, Inc. (EYPT) has an Altman Z-Score of -2.37, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is EyePoint, Inc.'s Piotroski F-Score?
EyePoint, Inc. (EYPT) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are EyePoint, Inc.'s earnings high quality?
EyePoint, Inc. (EYPT) reported a net loss of $232.0M while operations used $240.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can EyePoint, Inc. cover its interest payments?
EyePoint, Inc. (EYPT) reported an operating loss of $243.4M against $33K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is EyePoint, Inc.?
EyePoint, Inc. (EYPT) scores 46 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.